These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 26974181)

  • 1. Neurocognitive Changes in Selective Serotonin Reuptake Inhibitors-Treated Adolescents with Depression.
    Shehab AA; Brent D; Maalouf FT
    J Child Adolesc Psychopharmacol; 2016 Oct; 26(8):713-720. PubMed ID: 26974181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurocognitive Predictors of Clinical Improvement in Selective Serotonin Reuptake Inhibitor-Treated Adolescents with Major Depressive Disorder.
    Maalouf F; Bakhti R; Tamim H; Shehab S; Brent D
    J Child Adolesc Psychopharmacol; 2018; 28(6):387-394. PubMed ID: 29652529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Major Depressive Disorder in recovery and neuropsychological functioning: effects of selective serotonin reuptake inhibitor and dual inhibitor depression treatments on residual cognitive deficits in patients with Major Depressive Disorder in recovery.
    Herrera-Guzmán I; Gudayol-Ferré E; Herrera-Abarca JE; Herrera-Guzmán D; Montelongo-Pedraza P; Padrós Blázquez F; Peró-Cebollero M; Guàrdia-Olmos J
    J Affect Disord; 2010 Jun; 123(1-3):341-50. PubMed ID: 19896719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on attention and executive functions in patients with major depressive disorder.
    Herrera-Guzmán I; Herrera-Abarca JE; Gudayol-Ferré E; Herrera-Guzmán D; Gómez-Carbajal L; Peña-Olvira M; Villuendas-González E; Joan GO
    Psychiatry Res; 2010 May; 177(3):323-9. PubMed ID: 20385412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective Serotonin Reuptake Inhibitors and Serotonin and Noradrenaline Reuptake Inhibitors Improve Cognitive Function in Partial Responders Depressed Patients: Results from a Prospective Observational Cohort Study.
    Castellano S; Ventimiglia A; Salomone S; Ventimiglia A; De Vivo S; Signorelli MS; Bellelli E; Santagati M; Cantarella RA; Fazio E; Aguglia E; Drago F; Di Nuovo S; Caraci F
    CNS Neurol Disord Drug Targets; 2016; 15(10):1290-1298. PubMed ID: 27712575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative study of cognitive impairment between medicated and medication-free patients with remitted major depression: class-specific influence by tricyclic antidepressants and newer antidepressants.
    Nagane A; Baba H; Nakano Y; Maeshima H; Hukatsu M; Ozawa K; Suzuki T; Arai H
    Psychiatry Res; 2014 Aug; 218(1-2):101-5. PubMed ID: 24768252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Antidepressant Treatment on Symptom Measures of Attention in Adolescents with Depression: A Preliminary Open-Label Study.
    Choi CH; Lee J; Lee KH; Hong SB; Kim SH; Han JY; Kim JW; Cho SC; Kim JW
    J Child Adolesc Psychopharmacol; 2021 May; 31(4):288-293. PubMed ID: 33417814
    [No Abstract]   [Full Text] [Related]  

  • 8. [Selective serotonin reuptake inhibitors in major depressive disorder in children and adolescents (ratio of benefits/risks)].
    Hjalmarsson L; Corcos M; Jeammet P
    Encephale; 2005; 31(3):309-16. PubMed ID: 16142045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on memory and mental processing speed in patients with major depressive disorder.
    Herrera-Guzmán I; Gudayol-Ferré E; Herrera-Guzmán D; Guàrdia-Olmos J; Hinojosa-Calvo E; Herrera-Abarca JE
    J Psychiatr Res; 2009 Jun; 43(9):855-63. PubMed ID: 19128810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomised controlled trial of cognitive behaviour therapy in adolescents with major depression treated by selective serotonin reuptake inhibitors. The ADAPT trial.
    Goodyer IM; Dubicka B; Wilkinson P; Kelvin R; Roberts C; Byford S; Breen S; Ford C; Barrett B; Leech A; Rothwell J; White L; Harrington R
    Health Technol Assess; 2008 May; 12(14):iii-iv, ix-60. PubMed ID: 18462573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of short-term use of benzodiazepines on cognitive function of major depressive disorder patients being treated with antidepressants.
    Duan Y; Wei J; Geng W; Jiang J; Zhao X; Li T; Jiang Y; Shi L; Cao J; Zhu G; Zhang K; Yu X
    J Affect Disord; 2019 Sep; 256():1-7. PubMed ID: 31154087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New generation antidepressants for depression in children and adolescents: a network meta-analysis.
    Hetrick SE; McKenzie JE; Bailey AP; Sharma V; Moller CI; Badcock PB; Cox GR; Merry SN; Meader N
    Cochrane Database Syst Rev; 2021 May; 5(5):CD013674. PubMed ID: 34029378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in cognitive distortions and affectivity levels in adolescent depression after acute phase fluoxetine treatment.
    Stevanovic D; Zalsman G
    Cogn Neuropsychiatry; 2019 Jan; 24(1):4-13. PubMed ID: 30306831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of interleukin-6 and serotonin as biomarkers to predict response to fluoxetine.
    Manoharan A; Rajkumar RP; Shewade DG; Sundaram R; Muthuramalingam A; Paul A
    Hum Psychopharmacol; 2016 May; 31(3):178-84. PubMed ID: 27018372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-dependent changes in cognitive function with exercise augmentation for major depression: results from the TREAD study.
    Greer TL; Grannemann BD; Chansard M; Karim AI; Trivedi MH
    Eur Neuropsychopharmacol; 2015 Feb; 25(2):248-56. PubMed ID: 25453481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The percentage of cognitive impairment in patients with major depressive disorder over the course of the depression: A longitudinal study.
    Liu J; Chen Y; Xie X; Liu B; Ju Y; Wang M; Dong Q; Lu X; Sun J; Zhang L; Guo H; Zhao F; Li W; Zhang L; Li Z; Liao M; Li L; Zhang Y
    J Affect Disord; 2023 May; 329():511-518. PubMed ID: 36863474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching Selective Serotonin Reuptake Inhibitors in Adolescents with Selective Serotonin Reuptake Inhibitor-Resistant Major Depressive Disorder: Balancing Tolerability and Efficacy.
    Strawn JR; Mills JA; Croarkin PE
    J Child Adolesc Psychopharmacol; 2019 May; 29(4):250-255. PubMed ID: 30810350
    [No Abstract]   [Full Text] [Related]  

  • 18. Improvement in subjective and objective neurocognitive functions in patients with major depressive disorder: a 12-week, multicenter, randomized trial of tianeptine versus escitalopram, the CAMPION study.
    Jeon HJ; Woo JM; Lee SH; Kim EJ; Chung S; Ha JH; Fava M; Mischoulon D; Kim JH; Heo JY; Yu BH
    J Clin Psychopharmacol; 2014 Apr; 34(2):218-25. PubMed ID: 24525660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of remission speed and improvement of cognitive functions of depressed patients.
    Gudayol-Ferré E; Guàrdia-Olmos J; Peró-Cebollero M
    Psychiatry Res; 2015 Mar; 226(1):103-12. PubMed ID: 25619432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frontal-subcortical volumetric deficits in single episode, medication-naïve depressed patients and the effects of 8 weeks fluoxetine treatment: a VBM-DARTEL study.
    Kong L; Wu F; Tang Y; Ren L; Kong D; Liu Y; Xu K; Wang F
    PLoS One; 2014; 9(1):e79055. PubMed ID: 24427263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.